NIC
A fragment of nidogen-1 cleaved by cathepsin S, enabling non-invasive monitoring of basement membrane degradation and tumor microenvironment remodeling in cancer.
Key features and values
- Quantifies nidogen-1 fragments generated by cathepsin S activity.
- Reflects basement membrane degradation associated with tumor progression.
- Provides a non-invasive measure of extracellular matrix remodeling in oncology research.
- Supports monitoring of disease progression and response to therapies targeting tumor microenvironment.
- Applicable in research on cancers characterized by basement membrane disruption, such as non-small cell lung cancer.
- Facilitates evaluation of interventions aimed at modulating extracellular matrix degradation in tumors.
- Complements other biomarkers for a comprehensive assessment of tumor microenvironment dynamics.
Description
The NIC biomarker assay measures specific fragments of nidogen-1 resulting from cathepsin S-mediated cleavage, serving as an indicator of basement membrane degradation and tumor microenvironment remodeling in cancer. This non-invasive assay provides insights into extracellular matrix dynamics associated with tumor progression. By quantifying nidogen-1 degradation products, the NIC assay aids in monitoring disease progression, evaluating treatment efficacy, and understanding the underlying mechanisms of tumor microenvironment remodeling. It serves as a valuable tool in research settings for assessing the dynamics of extracellular matrix turnover in oncology.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
